Response of WHO to KEI letter regarding McKinsey, vaccine policy and competing interests
On 20 February 2011, Dr. Keiji Fukuda, Assistant Director-General – Health Security and Environment, World Health Organization, responded to KEI’s letter (16 February 2011) regarding McKinsey, vaccine policy and competing interests. Here is the response in full (email contacts have been redacted).
From: “Fukuda, Keiji”
Date: February 20, 2011 4:14:05 PM GMT+01:00
To: “Thiru Balasubramaniam”
Continue ReadingKEI letter to WHO regarding McKinsey, vaccine policy and competing interests
On 15 February 2011, the Co-Chairs of the WHO Open-Ended Working Group of Member States on Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccines and other benefits (OEWG) held a consultation with civil society. The Co-chairs of the OEWG are Ambassador J. Gomez-Camacho, Mexico and Ambassador B. Angell-Hansen, Norway. Continue Reading
WikiLeaks cable details UK/US strategy during IGWG negotiations in 2007
On 4 February 2011, WikiLeaks passed on to the UK newspaper, The Telegraph, a cable dated 1 November 2007 from the US Embassy in London entitled “UK AGREES WITH US APPROACH TO UPCOMING WHO INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION, AND IP” signed by “LEBARON“. Continue Reading
Noncommunicable diseases in the 2011 global public health agenda
Noncommunicable diseases (NCDs) enjoy a place of prominence on the global public health agenda in 2011. At the 128th WHO EB, the assembly was abuzz with news of a joint Russian and WHO initiative, the “First global ministerial conference on healthy lifestyles and noncommunicable disease control” to be held in Moscow on 28-29 April 2011 and the UN High-level Meeting of the General Assembly on Non-Communicable Diseases in September 2011.
Le Monde: L’OMS face à un nouveau conflit d’intérêts
The following is an article by Agathe Duparc which appeared on page four of the Sunday/Monday edition (23 January-24 January 2011) of Le Monde with a reference on the cover page. Below the article are two paragraphs providing readers with more background information on the World Health Assembly and the Executive Board. The third paragraph is the main quote highlighted in the print version. What is missing in this copy below is a cartoon accompanying the piece which shows a bespectacled man with a body of an octopus holding two syringes in a field of dollar signs. Continue Reading
Response to Mary Moran on managing conflicts of interest at the WHO CEWG
European members of WHO Executive Board take hard line on nomination of Novartis official to R&D group
At the 128th meeting of the WHO Executive Board (EB), the European members of the board are reportedly taking a hard line on the proposal by Switzerland to have Paul Herrling, an executive of Novartis, appointed to the WHO Consultative Expert Working Group (CEWG) on R&D financing. Our earlier blogs on this controversy are available here and here).
US government urges WHO to support Medicines Patent Pool: Extract of US intervention on draft WHO HIV/AIDS strategy 2011–2015
On Tuesday’s discussion at the 128th Executive Board on the Draft WHO HIV/AIDS strategy 2011–2015, the United States made a strong intervention (delivered by Dr. Nils Daulaire, Director, Office of Global Health Affairs, Department of Health and Human Services) in support of the Medicines Patent Pool drawing attention to the fact that the draft HIV/AIDS strategy while making reference to a more competitive market for ARVs, failed to recognized the importance of the Medicines Patent Pool.
Here below are the remarks of the US on this point:
Conflicts of Interest, and the WHO evaluation of the FRIND and the PDP Plus funding proposals by the CEWG
This note provide additional context for those who are just now following the issue of conflicts of interest and the WHO Consultative Expert Working Group (CEWG) on R&D Financing.
The CEWG follows a controversial, flawed and failed effort by an earlier group, the WHO Expert Working Group (EWG) on R&D Financing, to:
2011: The Year Ahead at WHO, WIPO and WTO
As 2011 unfolds, the following conferences and negotiations are expected to shape the knowledge governance landscape this year at WHO, WIPO and WTO.
World Health Organization